Guidelines for management of actual or suspected inadvertent intra-arterial injection of sclerosants.

Autor: Parsi K; International Union of Phlebology (UIP), Chatswood, NSW, Australia.; Australasian College of Phlebology (ACP), Chatswood, NSW, Australia.; Department of Dermatology, St Vincent's Hospital, Sydney, NSW, Australia.; Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.; Dermatology, Phlebology and Fluid Mechanics Laboratory, St Vincent's Centre for Applied Medical Research, Darlinghurst, NSW, Australia., De Maeseneer M; Department of Dermatology, Erasmus Medical Centre, Rotterdam, The Netherlands., van Rij AM; Australasian College of Phlebology (ACP), Chatswood, NSW, Australia.; Department of Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand., Rogan C; Interventional Radiology Society of Australasia (IRSA), Camperdown, NSW, Australia.; Department of Medical Imaging, Sydney Adventist Hospital, Sydney, NSW, Australia.; Macquarie University Hospital, Sydney, NSW, Australia., Bonython W; Faculty of Law, Bond University, Gold Coast, QLD, Australia., Devereux JA; University of Queensland Law School, University of Queensland, Saint Lucia, QLD, Australia., Lekich CK; Miami Private Hospital, Gold Coast, QLD, Australia., Amos M; Department of Anaesthesiology, Concord Hospital, Sydney, NSW, Australia., Bozkurt AK; International Union of Phlebology (UIP), Chatswood, NSW, Australia.; Department of Cardiovascular Surgery, Istanbul University, Istanbul, Turkie., Connor DE; Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.; Dermatology, Phlebology and Fluid Mechanics Laboratory, St Vincent's Centre for Applied Medical Research, Darlinghurst, NSW, Australia., Davies AH; European College of Phlebology, Rotterdam, The Netherlands.; Vascular Surgery, Imperial College London, Charing Cross and St Mary's Hospital, London, UK., Gianesini S; International Union of Phlebology (UIP), Chatswood, NSW, Australia.; Vascular Surgery, University of Ferrara, Ferrara, Italy., Gibson K; Lake Washington Vascular Surgeons, Bellevue, WA, USA., Gloviczki P; Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN, USA., Grabs A; Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.; Department of Vascular Surgery, St Vincent's Hospital, Sydney, NSW, Australia., Grillo L; International Union of Phlebology (UIP), Chatswood, NSW, Australia.; Vascular Surgery, University of Medical Sciences (UCIMED), San Jose, Costa Rica., Hafner F; Division of Angiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria., Huber D; Art of Vein Care, Wollongong, NSW, Australia., Iafrati M; American Venous Forum (AVF), East Dundee, IL, USA.; Vanderbilt University Medical Center, Vanderbuilt University, Nashville, TN, USA., Jackson M; Australian and New Zealand Society for Vascular Surgery(ANZSVS), Melbourne, VIC, Australia.; Department of Vascular Surgery, Gold Coast University Hospital, Gold Coast, QLD, Australia.; School of Medicine, Griffith University, Gold Coast, QLD, Australia., Jindal R; International Union of Phlebology (UIP), Chatswood, NSW, Australia.; Vascular Surgery, Fortis Hospital, Mohali, India., Lim A; Department of Dermatology, Royal North Shore Hospital, Sydney, NSW, Australia., Lurie F; International Union of Phlebology (UIP), Chatswood, NSW, Australia.; Jobst Vascular Institute, Toledo, OH, USA.; Section of Vascular Surgery, University of Michigan, Ann Arbor, MI, USA., Marks L; Australasian College of Phlebology (ACP), Chatswood, NSW, Australia.; Brighton Day Surgery, Adelaide, SA, Australia., Raymond-Martimbeau P; International Union of Phlebology (UIP), Chatswood, NSW, Australia.; Dallas Non-Invasive Vascular Laboratory and Vein Institute of Texas, Dallas, TX, USA., Paraskevas P; Paras Clinic, Melbourne, VIC, Australia., Ramelet AA; Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland., Rial R; International Union of Phlebology (UIP), Chatswood, NSW, Australia.; Vascular and Endovascular Surgery, University Hospital HM Madrid, Torrelodones, Spain., Roberts S; Victoria Vein Clinic, Melbourne, VIC, Australia., Simkin C; International Union of Phlebology (UIP), Chatswood, NSW, Australia.; Clínica Simkin, Buenos Aires, Argentina., Thibault PK; International Union of Phlebology (UIP), Chatswood, NSW, Australia.; Australasian College of Phlebology (ACP), Chatswood, NSW, Australia.; Central Vein and Cosmetic Medical Centre, Newcastle, NSW, Australia., Whiteley MS; The College of Phlebology, Guildford, UK.; The Whiteley Clinic, Guildford, UK.

Publikováno v: Phlebology [Phlebology] 2024 Dec; Vol. 39 (10), pp. 683-719. Date of Electronic Publication: 2024 Jul 24.

Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol.

Autor: Zhao H; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, China., Zhang X; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Tian P; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Luo Y; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Sun W; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Li Y; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Li J; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Gong T; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Yang Z; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; Department of Interventional Therapy, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China., Song P; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, China songpeng@cicams-sz.org.cn simonlixiao@263.net., Li X; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China songpeng@cicams-sz.org.cn simonlixiao@263.net.; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Hebei Cancer Hospital, Chinese Academy of Medical Sciences, Langfang, Hebei, China.

Publikováno v: BMJ open [BMJ Open] 2024 Dec 07; Vol. 14 (12), pp. e080805. Date of Electronic Publication: 2024 Dec 07.

Unleashing the potential: transarterial chemoembolization combined with intra-arterial infusion of bevacizumab for unresectable hepatocellular carcinoma.

Autor: Xie Q; Department of Hepato-Pancreato-Biliary & Gastric Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.; Postgraduate Training Base Alliance of Wenzhou Medical University, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China., Yang Y; Department of Hepato-Pancreato-Biliary & Gastric Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.; Postgraduate Training Base Alliance of Wenzhou Medical University, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China., Hao W; Department of Intervention, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China., Luo C; Department of Hepato-Pancreato-Biliary & Gastric Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China. luocong@zjcc.org.cn.

Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Dec; Vol. 26 (12), pp. 3075-3084. Date of Electronic Publication: 2024 May 27.

The Pretreatment Neutrophil-to-Lymphocyte Ratio as a Near-Term Prognostic Indicator in Patients with Locally Advanced Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy: A Propensity Score Matching Cohort Study.

Autor: Liu W; Department of Interventional Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.; Fujian Provincial Key Laboratory of Tumor Biotherapy, Fuzhou, Fujian, China., Zhang K; Department of Interventional Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.; Fujian Provincial Key Laboratory of Tumor Biotherapy, Fuzhou, Fujian, China., Chen S; Department of Interventional Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.; Fujian Provincial Key Laboratory of Tumor Biotherapy, Fuzhou, Fujian, China., Wang X; Department of Interventional Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.; Fujian Provincial Key Laboratory of Tumor Biotherapy, Fuzhou, Fujian, China., Yu W; Department of Interventional Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.; Fujian Provincial Key Laboratory of Tumor Biotherapy, Fuzhou, Fujian, China.

Publikováno v: British journal of hospital medicine (London, England : 2005) [Br J Hosp Med (Lond)] 2024 Nov 30; Vol. 85 (11), pp. 1-16. Date of Electronic Publication: 2024 Nov 13.

Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma.

Autor: Cao YZ; Department of Minimally Invasive Interventional Radiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangzhou, People's Republic of China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, People's Republic of China., Pan JY; Department of Minimally Invasive Interventional Radiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangzhou, People's Republic of China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, People's Republic of China., Zheng GL; Department of Minimally Invasive Interventional Radiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China.; State Key Laboratory of Oncology in South China, Guangzhou, People's Republic of China.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, People's Republic of China., An C; Department of Minimally Invasive Interventional Radiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China. anchao-1983@163.com.; State Key Laboratory of Oncology in South China, Guangzhou, People's Republic of China. anchao-1983@163.com.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, People's Republic of China. anchao-1983@163.com., Zuo MX; Department of Minimally Invasive Interventional Radiology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, People's Republic of China. zuomx@sysucc.org.cn.; State Key Laboratory of Oncology in South China, Guangzhou, People's Republic of China. zuomx@sysucc.org.cn.; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, People's Republic of China. zuomx@sysucc.org.cn.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Nov 14; Vol. 74 (1), pp. 24. Date of Electronic Publication: 2024 Nov 14.